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a  b  s  t  r  a  c  t
Low-molecular-weight  heparins  (LMWHs)  are  complex  anticoagulant  drugs,  made  from  heparin  porcine
mucosa  starting  material.  Enoxaparin  sodium  manufactured  by  Sanoﬁ  is  one  of the  most  widely  pre-
scribed  LMWHs  and has  been  used  since  1993  in the USA.  In  2010,  US  Food  and  Drug  Administration
approval  for supplying  generic  enoxaparin  was granted  to Sandoz  and  subsequently  to Amphastar.  Lit-
tle  is known,  however,  of the  differences  in  composition  of these  preparations.  In  this  study,  samples
from  several  batches  of  generic  enoxaparins  were purchased  on the  US  market  and  analyzed  with state
of the  art  methodologies,  including  disaccharide  building  blocks  quantiﬁcation,  nuclear magnetic  reso-
nance  (NMR),  and  a  combination  of orthogonal  separation  techniques.  Direct high-performance  liquid
chromatography  analysis  of  the different  enoxaparin  batches  revealed  distinct  process  ﬁngerprints  asso-
ciated  with  each  manufacturer.  Disaccharide  building  block  analysis  showed  differences  in  the  degree  of
sulfation,  the  presence  of glycoserine  derivatives,  as  well  as  in proportions  of  disaccharides.  Results  wereuclear magnetic resonance compared  by statistical  approaches  using multivariate  analysis  with  a  partial  least  squares  discriminant
analysis  methodology.  The  variations  were statistically  signiﬁcant  and  allowed  a clear distinction  to be
made  between  the enoxaparin  batches  according  to  their  manufacturer.  These  results  were  further  con-
ﬁrmed  by orthogonal  analytical  techniques,  including  NMR, which  revealed  compositional  differences  of
oligosaccharides  both  in  low-  and high-afﬁnity  antithrombin  fractions  of  enoxaparin.
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ration; Gal, galactose; GlcA, glucuronic acid; GPC, gel permeation chromatography;
ILIC, hydrophilic interaction liquid chromatography; HPLC, high-performance
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1. Introduction
Enoxaparin is a low-molecular-weight heparin (LMWH) widely
used in clinical practice for the prevention and treatment
of thromboembolism. Intestinal porcine heparin is used as a
starting material in manufacturing LMWH.  Heparin is biosyn-
thesized in mast cells and certain other types of granulated
cells as a proteoglycan. The heparin polysaccharide backbone
consists of a heteropolymer comprised of alternating sugar
units of 2-deoxy-2-sulfamido--d-glucopyranose (N-sulfated, or
N-acetylated, O-sulfated) and O-sulfated uronic acids (-l-iduronic
acid or -d-glucuronic acid). The arrangement of the disaccharide
building blocks within the macromolecule is governed by both its
biosynthesis and any microheterogeneity resulting from incom-
plete enzymatic reactions (such as deacetylation, N- and 2, 6-O
sulfations). Some particular domains, the antithrombin III (ATIII)
binding regions or alternatively pentasaccharide sequences, are 3-
O sulfated and are mainly responsible for the anticoagulant activity
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Nomenclature
U Uronic acid
IdoA l-Iduronic acid: -l–Idopyranosyluronic acid
GlcA d-Glucuronic acid: -d-glucopyranosyluronic acid
U 4,5-Unsaturated uronic acid, e.g. GlcA: 4-deoxy-
-l-threo-hex-enepyranosyluronic acid
GlcNAc d-N-Acetyl glucosamine: 2-deoxy-2-acetamido--
d-glucopyranose
GlcNS d-N-Sulfate glucosamine: 2-deoxy-2-sulfamido--
d-glucopyranose
2S 2-O-Sulfate
6S 6-O-Sulfate
3S 3-O-Sulfate
GalA d-Galacturonic acid
Structural symbols
IVa U-GlcNAc
IVs U-GlcNS
IIa U-GlcNAc,6S
IIIa U  2S-GlcNAc
IIs U-GlcNS,6S
IIIs U  2S-GlcNS
Ia U  2S-GlcNAc,6S
Is U  2S-GlcNS,6S
IVsgal GalA-GlcNS
IIsgal GalA-GlcNS,6S
The iduronic (id) or glucuronic (glu) structure of uronic acids is
indicated for oligosaccharides, e.g. Is IIIsid. Underlined disac-
charides have a 3-O-sulfated glucosamine
IIs U-GlcNS,3S,6S
Is U2S-GlcNS,3S,6S
IIsglu GlcA-GlcNS,3S,6S
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(originator, 24 products), enoxaparin sodium injection SandozIIa-IIsglu U-GlcNAc,6S- GlcA-GlcNS,3S,6S
f heparin by binding to antithrombin (AT) [1–3], a serine protease
nhibitor of the serpin family. Heparin acts as a cofactor for AT by
odifying its three-dimensional conformation, thus accelerating
he inactivation of clotting factors, most importantly, that of Factor
a and thrombin [3]. The initial step of the synthesis of enoxaparin
s the partial esteriﬁcation of the heparin polymer into a benzyl
ster. This is followed by a depolymerization step using sodium
ydroxide. The resulting mixture of polydisperse oligosaccharides
ncreases the degree of complexity due to side reactions altering
he endogenous disaccharide backbone during depolymerization
4]. Moreover, enoxaparin still contains ∼20% of the total of the
T-binding fraction.
The most recent advances in analytical and separation meth-
ds have permitted the isolation and sequencing of a number of
he active process-dependent components of enoxaparin [5]. It has
lso been demonstrated that the classic pentasaccharide sequences
re located at different sites along the oligosaccharide chains [6].
owever, despite such analytical advances, it remains impossible to
ake an exhaustive structural determination of all the components
f an enoxaparin mixture. Indeed, the correct methodology for the
roduction of generic enoxaparins has been a matter of extensive
cientiﬁc debate [7,8].
Analytical guidelines have been proposed for the production of
MWH generics. The ﬁrst generic enoxaparin was approved in 2010
or the US market. In parallel with agency recommendations (US
ood and Drug Administration, FDA; European Medicines Agency,
MA) [8,9], a scientiﬁc advisory panel from the International Soci-d Biomedical Analysis 115 (2015) 431–442
ety on Thrombosis and Haemostasis also provided some related
guidance [10]. As an example, they referred to the requirement
for an identical compositional disaccharide analysis between the
originator and the resulting biosimilar, taking into account the
natural structural dispersion of unfractionated heparin. The rec-
ommendation was to use AT afﬁnity chromatography as the best
tool to discriminate high- and low-afﬁnity fractions and to obtain
an efﬁcient mapping of the LMWH  [10]. In spite of these recom-
mendations, only one published work appears to have reported this
method speciﬁcally for the analysis of LMWH  [11].
High-performance liquid chromatography (HPLC) separations,
with the exception of some cases, were usually unable to resolve
mixtures above tetradecasaccharides [12], indicating that this tech-
nique alone is not satisfactory for comparability studies between
enoxaparins. Although alternative methods were proposed, no sin-
gle method can currently separate such a complex mixture. The
key tests used for the quality assurance of LMWHs  [13] are also
not designed for such comparison since they lack sufﬁcient res-
olution for separating their polysaccharide components. Zhang
et al. proposed a combination of ultra-performance size exclu-
sion chromatography/electrospray quadruple time-of-ﬂight-mass
spectrometry and capillary zone electrophoresis (CZE) for analyz-
ing the components of LMWHs  [14]. CZE was  also used to analyze
and quantify the building blocks of the various LMWHs, the most
complex being enoxaparin, following their exhaustive depolymer-
ization by heparinases. Although gel permeation chromatography
(GPC)/mass spectrometry (MS) can indeed be useful to identify
individual components, it is inappropriate to compare enoxaparin
batches, as quantiﬁcation by MS  is difﬁcult to achieve. It is also not
possible to obtain a complete chromatogram of the mixture due to
MS signal saturation. Li and coworkers proposed methods based on
a combination of liquid chromatography and Fourier transform MS
to analyze the composition of enoxaparin batches [15,16]. How-
ever, as previously highlighted, due to the absence of an AT afﬁnity
chromatography step, it was not possible to differentiate between
the high-afﬁnity oligosaccharides responsible for the anticoagulant
activity and the remaining low-afﬁnity material. Moreover, due to
the low resolution of hydrophilic interaction liquid chromatog-
raphy (HILIC), the oligosaccharide isomers of equivalent charge
density (positional isomers generated by sulfates substitution pat-
tern as well as the uronic acid conﬁguration) are hardly separated
[15].
A recent study assessed the identities of the originator and
330 generic enoxaparin batches available on the Brazilian market
[17]. This structural investigation, based on a comparison analyzing
the nuclear magnetic resonance (NMR) spectra of the origina-
tor compound on the GPC fractions, was, however, insufﬁcient to
characterize the structure of mixtures like enoxaparin. The basic
determination of the 1,6-anhydro compounds [18] was also not
performed. Furthermore, neither the chromatograms of enoxaparin
nor its enoxaparin fractions were shown in this work. Thus the
demonstration of the structural identity of different enoxaparin
batches remains to be investigated.
It is our view that at least three chromatographic methods with
orthogonal selectivity, such as afﬁnity chromatography, GPC, and
anion exchange, should be performed to allow, albeit with certain
limitations, the assessment of the consistency between enoxa-
parins from different manufacturers. The purpose of this study was,
therefore, to analyze and compare enoxaparin batches using ‘state
of the art’ analytical methods. Additional simple methods, such
as disaccharide compositional analysis as recommended in FDA
guidelines [8], are also included. Enoxaparin batches from Sanoﬁ(hereinafter ‘Sandoz’, 9 products), and the US generic enoxaparin
sodium injection Amphastar (hereinafter ‘Amphastar’, 4 products)
were studied and compared. Inter-batch variability was assessed
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nd the products compared for each manufacturer. At the time of
he study, the newly approved Teva enoxaparin generic was  not
vailable on the US market.
. Materials and methods
.1. Materials
Enoxaparin batches manufactured during the period 1999–2013
ere studied as they are supplied in powder form. Other sam-
les of generic enoxaparin purchased in the US were in syringes
nd were usually present at 100 mg/ml. All enzyme lyases from
lavobacterium heparinum (heparinase I [EC 4.2.7], heparinase II [no
C number], and heparinase III [EC 4.2.2.8]) were obtained from
rampian Enzymes (Aberdeen, UK). All other reagents and chemi-
als were of the highest quality available. Water was puriﬁed using
 Millipore Milli-Q puriﬁcation system (Darmstadt, Germany).
.2. Exhaustive depolymerization by the heparinase mixture
Enoxaparin samples were digested into a mixture of disac-
harides and tetrasaccharides using a mixture of enzyme lyases
heparinases) to quantify the building blocks of the examined sam-
le as described previously for heparin samples [19].
.2.1. Enzymatic digestion
The digestion of enoxaparin samples (20 l of a 20 mg/ml solu-
ion in water) was performed at room temperature for 48 h in a
otal volume of 170 l containing 20 l of a mixture of heparinase
, II, and III, where each heparinase was at 0.5 IU/ml in a potassium
hosphate buffer (pH 7.0; 10 mM KH2PO4 and 0.2 mg/ml  of bovine
erum albumin [BSA]) and 120 l of sodium acetate buffer (pH 7.0;
00 mM)  containing Ca(OAc)2 (2 mM)  and BSA (0.5 mg/ml) [19].
.2.2. Analysis of heparin digests by strong anion exchange (SAX)
hromatography
Digested samples of 4 l to 10 l were then injected on a col-
mn (250 × 3.2 mm)  ﬁlled with Spherisorb SAX of 5 m particle
iameter (Waters, Guyancourt, France). The column temperature
as set at 50 ◦C. Mobile phase A consisted of NaH2PO4 (pH 3.0;
.8 mM),  while mobile phase B was an aqueous solution of NaH2PO4
1.8 mM)  and 1 M NaClO4 (pH 3.0; 1 M).  A linear gradient (t 0 min%B
; t 20 min%B 35; t 50 min%B 100) was applied to the column for
he elution of the samples at a ﬂow rate of 0.45 ml/min. Dou-
le UV detection was monitored at 232 nm and 202–247 nm.  The
-acetylated oligosaccharide selective signal (202–247 nm)  is the
esult of the subtraction of the 202 nm wavelength UV signal from
he 247 nm reference signal, as previously described [20].
.2.3. Principle of quantiﬁcation
The quantiﬁcation was based on the well-established assump-
ion of the uniformity of the molar response coefﬁcients at 232 nm
maximum of UV absorbance of unsaturated oligosaccharides
btained after heparinase digestion) [21,22]. The principle and the
hromatographic method are identical to those used in the U.S.
harmacopeia for the quantiﬁcation of 1,6-anhydro derivatives in
noxaparin [18]. The percentage w/w for each component was
iven by the following formula:
w
w
= 100 × Mw1 × Ai
xMwx × Ax
here Mwi and Ai represent the molecular weight and the
hromatographic area at 232 nm of the assayed component i,
espectively; Mwx and Ax represent the molecular weight and the
hromatographic area, respectively, of either the peak X or the zoned Biomedical Analysis 115 (2015) 431–442 433
X speciﬁed by its retention time. The sum is related to all the com-
ponents eluted. The molecular weights of the peaks are given as
described in Fig. 1, according to their identiﬁcation on the chro-
matogram.
The precision of the method for LC evaluation of disaccharide
building blocks was  assessed in its application for the quantiﬁca-
tion of 1,6-anhydro derivatives in enoxaparin [18]. Repeatability
experiments showed a relative standard deviation (RSD) of 1.3%, as
based on the percentage of oligosaccharide chains in enoxaparin
with 1,6-anhydro sequences (sum of three 1,6-anhydro building
blocks [Fig. 2]).
The identiﬁcation of chromatographic peaks has been already
described in the case of heparin. The identity of the supplementary
peaks eluted from the enoxaparin batches are illustrated in Fig. 2.
The initiation of heparin biosynthesis occurs at a spe-
ciﬁc sequence, glucuronic acid-galactose-galactose-xylose-serine
(GlcA—Gal-Gal-Xyl-Ser), called glycoserine. The original glycoser-
ine tetrasaccharide GlcA 1-3 Gal 1-3 Gal 1-4 Xyl 1-0-Ser
(Glyser), obtained through cleavage by heparinase III [23], is
found in heparinase digests of crude heparins. However, it was
observed that the serine end could, as a result of the Maillard
reaction, generate coloration in the resulting enoxaparin batches
that could diminish their shelf-life. Oxidation steps were, there-
fore, inserted in the puriﬁcation process of heparin to modify
the glycoserines [24]. The two oxidized glycoserine tetrasaccha-
rides Glyserox1 and Glyserox2 (for structures, see Table 1S in
the Supplementary data-a1 ﬁle) were identiﬁed and were eluted
on the ﬁrst part of the chromatogram of the digest as shown in
Fig. 1. To enable a suitable comparison of the glycoserine deriva-
tives present in the different enoxaparin batches, the amounts of
each of these derivatives were added to give a sum of glycoserines
((Glycoserine)). The sulfate/carboxylate ratio was  calculated by
adding the sulfate/carboxylate ratio contributions of all building
blocks, taking into account their respective abundance.
2.3. Chromatographic methods for direct analysis of enoxaparin
batches
The orthogonal analytical methodology applied to enoxaparin
batches is summarized in Fig. 3.
2.3.1. Afﬁnity chromatography on immobilized antithrombin (AT)
An AT-sepharose column (30 cm × 7 cm)  prepared by coupling
2 g human AT to cyanogen bromide (CNBr)-activated Sepharose 4B
(Sigma, Saint-Quentin Fallavier, France) as described by Höök et al.
[25] was  used to separate high- and low-afﬁnity fractions using two
injections of 100 mg  of the enoxaparin batch. All experimental data
are provided in the Supplementary data-a1 ﬁle (Fig. 1S).
2.3.2. Gel permeation chromatography (GPC)
GPC was used to separate the LMWHs  according to the size of
their oligosaccharide constituents (ranging from tetrasaccharides,
hexasaccharides, octasaccharides, up to tetradecasaccharides).
A column (100 cm × 2.6 cm)  ﬁlled with Bio Gel P-30 (Bio-Rad,
Marnesla-Coquette, France) circulated with NaClO4 (0.2 N) at a ﬂow
of 0.6 ml/min permitted the injection of 50–200 mg of the prod-
uct diluted in the mobile phase. High- and low-afﬁnity fractions
obtained from the afﬁnity chromatography step were injected on
this column, and double UV detection at 202 nm and 232 nm and
refractometry were performed. Examples of GPC chromatograms
of high- and low-afﬁnity enoxaparin are shown in Fig. 4. High-
and low-afﬁnity fractions from tetrasaccharides to tetradecasac-
charides were then collected and desalted on Sephadex G-10 (GE
Healthcare, Vélizy-Villacoublay, France). After lyophilization, frac-
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Fig. 1. Enoxaparin batches depolymerized by heparinase enzymes and separated by strong anion exchange chromatography (black lines: UV 234 nm;  red lines: UV
202–242  nm). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Speciﬁc building blocks of enoxaparin present in the supplementary peaks eluted from enoxaparin.
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3ig. 3. Orthogonal analytical methodology used for the direct analysis 
etyltrimethylammonium–strong anion exchange, GPC: gel permeation chromatog
ions were ready for analysis either by cetyltrimethylammonium
CTA)-SAX HPLC or NMR.
.3.3. Cetyltrimethylammonium (CTA)-SAX chromatography
CTA-SAX was used to analyze fractions puriﬁed by afﬁnity chro-
atography and GPC. Columns ﬁlled with Kinetex C18 2.6 m
articles (Phenomenex, Le Pecq, France) were prepared following a
rocedure described previously [20]. The mobile phases consisted
f aqueous NH4CH3SO3 (pH 2.5; concentrations varying between 0
nd 2 M)  and a ﬂow rate of 0.22 ml/min. The column temperature
as 40 ◦C and dual UV detection was performed at 232 nm and at
02–242 nm as described previously [20].
.4. NMR
Enoxaparin tetradecasaccharide fractions were prepared by dis-
olving 2–5 mg  of sample in 0.6 ml  of D2O 99.99% (Euriso-Top,
aint-Aubin, France). NMR  spectra were recorded at 600 MHz
n an Avance 600 spectrometer (Bruker BioSpin, Wissembourg,
rance) equipped with a 5 mm Triple Resonance (TXI) cryoprobe
t a temperature of 25 ◦C, with pre-saturation of the residual
ater signals and with recycle delay of 3 s. 2D heteronuclear sin-
le quantum correlation spectra (HSQC) spectra were recorded
ith carbon decoupling during acquisition, using phase-sensitive
cho/antiecho time proportional phase incrementation (TPPI) gra-
ient selection (Bruker BioSpin standard sequence library). The
olarization transfer delay was calculated with a 1JC H coupling
alue of 150 Hz. Experiments were zero-ﬁlled and multiplied with
ine-bell apodization prior to Fourier transformation.
.5. Statistical analysis and data processingThe percentages weight/weight (% w/w) in the heparin chain of
he 17 preselected building blocks were quantiﬁed for each of the
7 batches of enoxaparin tested (24 batches from Sanoﬁ, and 13ifferent sources of batches of enoxaparin. AT: antithrombin, CTA-SAX:
, NMR: nuclear magnetic resonance.
from US generics: 9 from Sandoz and 4 from Amphastar). For con-
ﬁdentiality reasons, anonymous ID numbers were assigned to all
batches (SAE1 to SAE24 for Sanoﬁ batches, SZE1 to SZE9 for Sandoz
batches, and AME1 to AME4 for Amphastar batches).
2.5.1. Exhaustive depolymerization by the heparinase mixture
From these data, average values, standard deviations (SDs), and
SD/mean ratios were calculated for each building block.
2.5.2. Chemometrics and data analysis
A multivariate analysis utilizing a partial least squares discrim-
inant analysis (PLS-DA) was used to compare the three producer
groups of enoxaparin batches using the 17 preselected building
blocks of the heparin chain. This popular technique in the ﬁeld of
chemometrics is especially suitable when the investigation con-
cerns the prediction of a categorical variable from multi-collinear
and non-normal predictors, which is common in chemical data
analysis [26–29]. In the current study, it will be used to determine
variables (from the 17 building blocks) enabling differentiation to
be made between enoxaparins from different sources.
Prior to PLS-DA, all of the variables were centered and scaled to
unit variance for comparison. The non-linear iterative partial least
squares (NIPALS) algorithm was used to perform the PLS regression.
The number of PLS components was selected by cross-validation.
After an initial PLS-DA analysis using all 17 variables, the most
discriminating variables were selected from the variable impor-
tance in the projection (VIP) plot. Only those variables with VIP
values higher than 1 were considered. These selected variables
were then used to build a reduced PLS-DA model.
Discriminatory and predictive properties of models were
assessed by the R2 and Q2 values provided by the software. The
model validation was performed by cross-validation (based on 100
permutations).
In parallel, since the hypotheses of normality and homogeneity
of variances were not fulﬁlled, a non-parametric univariate analysis
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Fig. 4. Gel permeation chromatography (GPC) chromatograms of high-afﬁnity (thin lines) and low-afﬁnity (thick lines) enoxaparin. (A) Detection using a refractometer. (B)
Detection using UV (black lines 232 nm;  red lines: 202 nm). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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Table  1
Comparison of the average values, standard deviations (SD), and SD/average ratios obtained for the building blocks calculated from the originator Sanoﬁ enoxaparin batches
(Tables 2S and 3S in Supplementary data-a1 ﬁle), generic Sandoz enoxaparin batches (Table 4S in Supplementary data-a1 ﬁle), and generic Amphastar enoxaparin batches
(Table  5S in Supplementary data-a1 ﬁle). Values are weight/weight (w/w) percentages of the building blocks obtained after exhaustive depolymerization of enoxaparin by
heparinases.
Sanoﬁ Sandoz Amphastar
Building blocks Average SD % SD/ave Average SD % SD/ave Average SD % SD/ave
IVa 1.7 0.2 12 1.3 0.2 18 0.7 0.2 29
(Glyser) 1.5 0.4 26 1.3 0.3 19 0.3 0.0 14
IVsgal 0.2 0.1 30 0.2 0.1 35 0.2 0.1 29
IVs  2.0 0.2 11 1.6 0.1 9 1.4 0.1 5
IIa  2.6 0.3 10 2.7 0.3 10 2.3 0.1 4
IIIa 1.2 0.1 7  1.0 0.1 7 1.1 0.1 14
IIsgal 1.0 0.4 44 1.5 0.3 17 1.8 0.3 14
IIs  8.6 0.3 4 8.9 0.3 3 8.5 0.3 4
IIIs  5.5 0.2 4 5.0 0.1 3 4.9 0.2 4
Is1,6anhydr 1.1 0.2 16 1.1 0.2 20 0.7 0.0 6
Ia  1.3 0.3 19 1.4 0.1 7 1.4 0.0 2
IIa-IVsglu 0.9 0.1 9 0.8 0.1 8 0.8 0.3 32
Is  58.9 0.7 1 59.2 1.0 2 62.3 0.9 1
IIa-IIsglu 4.2 0.2 4 4.6 0.2 5 4.3 0.3 6
Is-IdoA2S 1.3 0.2 18 1.6 0.2 12 1.5 0.4 27
Is-Isid1,6anhydr 2.5 0.3 10 2.5 0.5 18 2.0 0.2 11
Sulf/Carb 2.4 0.0 1 2.4 0.0 1 2.5 0.0 1
Table 2
Wilcoxon pairwise comparison tests of the 5 most discriminant variables (variable importance in projection [VIP] > 1). p-values were corrected using the Bonferroni–Holm
adjustment for multiple comparisons.
Comparison IVa
∑
(Glyser) IVs IIIa IIIs
Sanoﬁ Sandoz p = 0.0051 p = 0.2221 p = 0.0005 p = 0.0001 p < 0.0001
Sanoﬁ Amphastar p = 0.0051 p = 0.0052 p = 0.0033 p = 0.0860 p = 0.0037
Sandoz Amphastar p = 0.0184 p = 0.0129 p = 0.0316 p = 0.4808 p = 0.7530
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as chosen ﬁrst to estimate the Spearman correlation coefﬁcients.
he differences in the median of the % w/w building blocks between
he three groups of enoxaparin batches were then tested globally
sing the non-parametric Kruskal–Wallis test at a 5% signiﬁcance
evel and, then post hoc, two by two, with Wilcoxon tests at a 5% sig-
iﬁcance level corrected for multiplicity by the Bonferroni–Holm
djustment.
.5.3. Software
The PLS-DA was performed using SIMCA-PTM software (version
3.0.0.0 published by Umetrics AB, Umea, Sweden) [30], and uni-
ariate analysis was performed using SAS/STAT® software (version
.2 of the SAS System for Windows, SAS Institute, Cary, NC) [31]
nd JMP® software (version 10.0.1) [32].
. Results and discussion
.1. Exhaustive depolymerization by the heparinase mixture
This study, based on determination of building blocks, was con-
ucted after exhaustive depolymerization by heparinases on all
he samples. Complete data analysis is provided in the Supple-
entary data-a1 ﬁle (Tables 2S to 5S). The average values, SDs,
nd SD/average ratio calculated for each building block of the 37
ifferent enoxaparin batches are shown in Table 1.
As a general feature, the high SD/average ratios (>10%) were
btained with those building blocks, such as IVsgal, IVs, IIa,
IIIa, and Ia, which were present in small amounts. Higher
eviation ratios were also obtained for the IIsgal and IVsgal
isaccharides formed by alkaline 2-O  desulfation. However, as
his side reaction occurs during the preparation of both enoxa-
arin and heparin, its magnitude is dependent upon the heparine medians of parameter for the two compared groups are signiﬁcantly different at
source used as starting material. This is not necessarily the same
source between manufacturers. The case of the 1,6-anhydro build-
ing blocks is also notable. The depolymerization of Is-Isid1,6anhydr
into Is1,6anhydr by heparinase II is difﬁcult and can possibly be
incomplete. In that case, lower Is1,6anhydr values occur with higher
levels of Is-Isid1,6anhydr. As a result, high SD/average ratios for
Is1,6anhydr and Is-Isid1,6anhydr only produce small differences
in the depolymerization by heparinases of these particular build-
ing blocks. Enoxaparin batches from Amphastar showed lower
averages for IVa,
∑
(Glyser) and higher averages for Is  when
compared with enoxaparin batches from Sanoﬁ and Sandoz.
3.2. Analysis of disaccharide building blocks quantiﬁcation
The reduced PLS-DA model was  built from 8 variables (IIIs,
IIIa, IIa-IIsglu, Is, Sulf/Carb,
∑
(Glyser), IVa, and IVs) that
had a VIP > 1 (Fig. 5A). Using the two PLS-DA components (c1 and c2),
the cross-validated model was highly valid and predictive for each
group of batches. In fact, for each group of batches, the intercept
of Q2cum was negative (−0.238 for Sanoﬁ batches, −0.208 for San-
doz batches, and −0.225 for Amphastar batches). The PLS-DA also
demonstrated good discriminatory and predictive performances,
with R2Y = 0.68 (R2Yc1 = 0.42 and R2Yc2 = 0.26) and Q2Y = 0.63.
Among the 17 building blocks, IIIs, IIIa, IIa-IIsglu, Is,
Sulf/Carb,
∑
(Glyser), IVa, and IVs showed the highest discrim-
inatory power, with a VIP higher than 1 (Fig. 5A). The IVsgal, Ia,
and IIa-IVsglu building blocks were the least discriminating vari-
ables from the VIP plot, with a VIP around 0.7 (< to the threshold
of 1) (Fig. 5A). A Kruskal–Wallis test, at a 5% signiﬁcance level,
conﬁrmed that the origin of the enoxaparin batches had no signiﬁ-
cant inﬂuence on these building blocks (p-value [IVsgal] = 0.2011,
p-value [Ia] = 0.9473, p-value [IIa-IVsglu] = 0.1085).
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Fig. 5. (A) Variable importance in projection (VIP) plot of the initial partial least squares discriminant analysis (PLS-DA) model. (B) Score scatter plot (t1/t2) of the reduced
P  enox
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t
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t
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DLS-DA  model. Green circles or ID numbers SAE01 to SAE24 correspond to Sanoﬁ
noxaparin batches; red circles or ID numbers AME01 to AME04 correspond to Amp
odel:  PLS weight plot corresponding to Fig. 5B . (D) Spearman correlation coefﬁci
Fig. 5B shows the t1/t2 score of the reduced PLS-DA model and
he corresponding weights (w × c1/w × c2) of the samples. The PLS-
A model clearly shows clustering between the samples from each
f the three manufacturers. It may  be noted that the group of
mphastar enoxaparin batches (red circles, ID numbers AME01
o AME04) has no overlap with the other groups of enoxaparin
atches from Sandoz (blue circles, ID numbers SZE01 to SZE09)
nd Sanoﬁ (green circles, ID numbers SAE01 to SAE24). Two PLS-
A components explain 68% of the Y-variance. These results showaparin batches; blue circles or ID numbers SZE01 to SZE09 correspond to Sandoz
r enoxaparin batches. (C) Loading scatter plot (w × c1/w × c2) of the reduced PLS-DA
f the 8 most discriminant variables (VIP > 1). * Denotes signiﬁcant correlations.
clear discrimination between the enoxaparin batches from all three
manufacturers.
The loading scatter plot (w × c1/w × c2) of the reduced PLS-DA
model shown in Fig. 5C enabled the determination of those vari-
ables that contribute strongly to the separation of the different
batches. It also permitted any correlations existing between the
variables and the group of enoxaparin batches to be identiﬁed.
Correlations between variables could also been interpreted from
their Spearman correlation coefﬁcients  and their signiﬁcance at
the 5% level (Fig. 5D). From this it can be seen that the IIIs, IVs,
P.A.J. Mourier et al. / Journal of Pharmaceutical an
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Fig. 6. (A) Cetyltrimethylammonium–strong anion exchange (CTA-SAX) chro-
matograms of originator Sanoﬁ enoxaparin and generic Sandoz and Amphastar
enoxaparin batches as they are (black line: UV 232 nm;  red line: UV 202–242 nm). (B)
CTA-SAX chromatograms of Sanoﬁ enoxaparin as it is, and its high-afﬁnity and low-
afﬁnity fractions (black lines: UV 232 nm;  red lines: UV 202–242 nm). (C) Percentage
of glycoserines ((Glyser)) obtained after exhaustive depolymerization by hepari-
nases of high- and low-afﬁnity fractions as a function of the chain length (number
of  disaccharides). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)d Biomedical Analysis 115 (2015) 431–442 439
IVa, IIIa, and
∑
(Glyser) were positively correlated (r > 0.51), as
were the Is  and Sulf/Carb (r = 0.63). The IIIs, IIIa, and IVs
were negatively correlated to IIa-IIsglu (r ≥ 0.41).
∑
(Glyser) and
IVa were negatively correlated to Is and Sulf/Carb (r ≥ 0.49).
Is was  not correlated to IIIs (p-value = 0.0738), IIIa (p-
value = 0.1228), or IIa-IIsglu (p-value = 0.5589). IIa-IIsglu was not
correlated to Is  (p-value = 0.5589),
∑
(Glyser) (p-value = 0.2667),
and Sulf/Carb (p-value = 0.5224).
Other variables discriminating between the different batches
had signiﬁcantly different medians according to the Wilcoxon pair-
wise comparison test as shown in Table 2. There were signiﬁcant
differences in the IVs, IIIs, IIIa, IVa, and IIa-IIsglu present in
the Sanoﬁ and Sandoz batches. Signiﬁcant differences also occurred
for
∑
(Glyser), IVa, IVs, IIIs, Is, and Sulf/Carb in the compari-
son between the Sanoﬁ and Amphastar batches, and for
∑
(Glyser),
IVa, Is, and Sulf/Carb present in the batches from Sandoz and
Amphastar.
Results from the univariate and the multivariate analyses, there-
fore, allowed improved characterization of the composition of the
disaccharide building blocks from the three different manufac-
turers of enoxaparin. In general, the Sandoz enoxaparin batches
possessed signiﬁcantly higher values of IIa-IIsglu but signiﬁcantly
lower values of IIIa, IIIs, IVs, and IVa than the Sanoﬁ enoxa-
parin batches. Compared with Sanoﬁ enoxaparin, signiﬁcantly
higher values of Sulf/Carb and Is  and signiﬁcantly lower values
of
∑
(Glyser), IVa, IVs, IIIs, and IIIa were identiﬁed in the
Amphastar enoxaparin batches. Compared to Sanoﬁ enoxaparin,
approximately 3% of the building blocks, i.e. low sulfated disac-
charides concentrated on the reducing ends of the oligosaccharide
chains, are missing in the Amphastar batches. The higher degree
of sulfation of the Amphastar oligosaccharide chains (% Is  and
Sulf/Carb ratio) could, at least partly, be the consequence of the
missing low sulfated sequences.
3.3. CTA-SAX chromatograms of enoxaparin fractions
The CTA-SAX chromatographic analyses of the Sanoﬁ and the
generic Sandoz and Amphastar enoxaparin batches are shown in
Fig. 6A. The whole oligosaccharide mixture present in the prod-
uct and its diverse chain lengths can be shown in this type of
chromatogram. These oligosaccharides possessed, however, an
unsaturated uronic acid on their non-reducing end, giving a molar
signal by UV detection at 232 nm.  This resulted in emphasis on the
presence of shorter oligosaccharidic chains (disaccharides to hex-
asaccharides representing only about 15% of the batches and 2–3%
of the active ingredients) in the samples.
The disaccharides were eluted at retention times of less than
20 min, with obvious differences being observed for the three dif-
ferent sources of enoxaparin. These differences could be dependent
on the last steps of puriﬁcation of enoxaparin and, more speciﬁ-
cally, on the respective workup conditions of the depolymerization
process. These differences in composition between manufacturers
were also visible for the tetrasaccharides. While these results are
informative for the overall enoxaparin complex mixture, the inabil-
ity to resolve larger components than hexasaccharides means that
there is a strong overlap between the constituent molecules. In
order to obtain a more precise view on the higher oligosaccha-
rides composition, the use of additional orthogonal methods, such
as those described in the scheme shown in Fig. 3, are essential.
This point is emphasized in the present study by comparing eluted
AT fractions. Fig. 6B shows a comparison of the high- and low-
afﬁnity AT fractions and the originator Sanoﬁ enoxaparin. Despite
the high-afﬁnity fraction constituting 20–25% w/w of the batch, its
higher molecular weight means that it can barely be detected in
the chromatogram of the generic enoxaparin batch. Consequently,
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pig. 7. Cetyltrimethylammonium–strong anion exchange (CTA-SAX) chromatogram
V  202–242 nm). (A) High-afﬁnity dodecasaccharides. (B) High-afﬁnity tetradecasac
nterpretation of the references to color in this ﬁgure legend, the reader is referred 
he chromatogram of the low-afﬁnity fraction appears rather simi-
ar to that of the originator enoxaparin source, thus reinforcing the
mportance of using orthogonal methods to assess precisely the
ompositional aspects and to overcome overlapping broad peaks.
The subsequent use of CTA-SAX chromatography on the low-
fﬁnity samples and the AT afﬁne fractionated according to the
ize of their components, i.e. disaccharides, tetrasaccharides, hex-
saccharides, up to tetradecasaccharides, by GPC resulted in the
eneration of an important amount of data. The most relevant
esults are shown here, while the remainder are provided as Sup-
lementary data-a1 and a2 ﬁles (Figs. 2S–10S). The data presented
n this paper are focused primarily on the glycoserine-containing
ractions. The percentage of oligosaccharide chains containing a
lycoserine moiety at the reducing end increases with increas-
ng chain length (Fig. 6C) and, as a result, these fractions mainly
orrespond to those chains longer than dodecasaccharides.
High-afﬁnity dodecasaccharides and tetradecasaccharides from
noxaparin from the three manufacturers are compared in Figs. 7A
nd 7B. A similar comparison of the low-afﬁnity fractions is
hown in Figs. 7C and 7D. The glycoserine-containing oligosaccha-
ides can easily be identiﬁed. The low sulfation of the reducing
nd saccharides induces a low retention time on the chro-
atogram (tr < 45 min  for dodecasaccharides and tr < 50 min  for
etradecasaccharides). These compounds are also highly acetylated
nd, consequently, strongly absorb at the UV selective signal of
02–242 nm.
Of all the fractions studied, only the Amphastar generic enoxa-
arin contained the higher sulfated components. Low sulfatedhe Sanoﬁ, Sandoz, and Amphastar enoxaparins (black lines: UV 232 nm;  red lines:
des. (C) Low-afﬁnity dodecasaccharides. (D) Low-afﬁnity tetradecasaccharides. (For
 web  version of this article.)
oligosaccharides, i.e. the less retained compounds on the chro-
matograms, were not detected. The reason for this absence remains
unclear but is probably dependent upon the manufacturing process.
This observation also correlated with the results obtained after the
exhaustive depolymerization by heparinases, indicating the pres-
ence of signiﬁcantly lower amounts of glycoserine markers in the
Amphastar batches.
3.4. NMR  analysis of enoxaparin fractions
In view of the differences described above, the Sanoﬁ and
Amphastar enoxaparins were further compared by NMR  spec-
troscopy using two-dimensional 1H-13C HSQC spectra. These
results are all supplied in the Supplementary data-b ﬁle (Figs. 11S to
19S). Amphastar enoxaparin batches, as well as their low- and high-
afﬁnity fractions, exhibited spectra where the characteristic signal
of glycoserine moieties was very weak and signiﬁcantly less impor-
tant than in those present in the Sanoﬁ batches. Since glycoserines
are mainly present in the high-molecular-weight fractions (Fig. 6C),
the low- and high-afﬁnity fractions above dodecasaccharides
obtained from Amphastar and Sanoﬁ showed different spectra due
to the lack of glycoserine-containing oligosaccharides in Amphastar
batches. These observations conﬁrmed the data obtained from both
the heparinase exhaustive depolymerization step as well as that
from the CTA-SAX chromatograms. In the Amphastar enoxaparin
batches, the very low presence of glycoserine ends and neigh-
boring disaccharides (IVa and IVS) demonstrated the loss of
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pproximately 4–6 low sulfated saccharide units, thus increasing
he sulfate/carboxylate ratio signiﬁcantly.
. Conclusions
We  have deﬁned a protocol for the analysis of originator and
eneric batches of enoxaparin. This study summarizes our ana-
ytical ﬁndings on representative batches of originator (Sanoﬁ)
nd generic (Sandoz and Amphastar) enoxaparin. ‘State of the
rt’ methods, such as disaccharide building blocks analysis and
irect CTA-SAX chromatography, were able to differentiate the
noxaparins supplied from three different manufacturers. Qualita-
ive analysis of the CTA-SAX chromatogram (Fig. 6A) was helpful
o observe differences in the enoxaparin manufacturing process
orkup and highlight characteristic ﬁngerprint differences in their
i- and tetrasaccharide compositions. Thus, the qualitative anal-
sis of disaccharide building blocks described here shows that
mphastar enoxaparin has, for example, a signiﬁcantly higher
egree of sulfation and a lower glycoserine derivative content than
oth the Sanoﬁ and Sandoz enoxaparins. These differences can be
lso observed in the compositional analysis of the polysaccharide
ixtures (without enzymatic pretreatment) by using a combina-
ion of orthogonal methods, including NMR. They appear both in
he AT afﬁne oligosaccharide and non-afﬁne fractions of enoxaparin
roducts. The differences between the Sanoﬁ and Sandoz enoxa-
arins are less intuitive, but are clearly revealed by the PLS-DA
tatistical analysis of their building blocks, which also show sig-
iﬁcant discrimination between the enoxaparins sourced from all
hree manufacturers. The clinical signiﬁcance of these structural
ifferences continues to be evaluated.
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